{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:12:11Z","timestamp":1793070731852,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jchf.2021.09.004","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T15:53:31Z","timestamp":1638978811000},"page":"73-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":352,"title":["A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced\u00a0Ejection\u00a0Fraction"],"prefix":"10.1016","volume":"10","author":[{"given":"Jasper","family":"Tromp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Ouwerkerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans L.","family":"Hillege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Mark","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2021.09.004_bib1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ejhf.1585","article-title":"Heart failure around the world","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.004_bib2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jchf.2021.09.004_bib3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart\u00a0Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart\u00a0Failure Society of Amer","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.09.004_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2021.09.004_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib7","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/ejhf.1633","article-title":"Dapagliflozin in heart failure: new frontiers","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.004_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2021.09.004_bib10","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib12","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/CIRCULATIONAHA.120.048365","article-title":"Victims of success in failure","volume":"142","author":"Lam","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.09.004_bib13","first-page":"1","article-title":"Treatment of HF in an era of multiple therapies: statement from the HF Collaboratory","volume":"9","author":"Bhatt","year":"2021","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.09.004_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jchf.2021.09.004_bib15","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/sim.5453","article-title":"Quantifying the impact of between-study heterogeneity in multivariate meta-analyses","volume":"31","author":"Jackson","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib16","series-title":"An Introduction to Meta-Analysis With R","first-page":"3","author":"Schwarzer","year":"2015"},{"key":"10.1016\/j.jchf.2021.09.004_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.jchf.2021.09.004_bib18","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib19","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/bimj.201800167","article-title":"Network meta-analysis of multicomponent interventions","volume":"62","author":"R\u00fccker","year":"2020","journal-title":"Biometrical J"},{"key":"10.1016\/j.jchf.2021.09.004_bib20","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jclinepi.2012.07.012","article-title":"Calculating additive treatment effects from multiple randomized trials provides useful estimates of combination therapies","volume":"65","author":"Mills","year":"2012","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jchf.2021.09.004_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jchf.2021.09.004_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLOS Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib23","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jchf.2021.09.004_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"Br Med J"},{"key":"10.1016\/j.jchf.2021.09.004_bib25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence - Indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jchf.2021.09.004_bib26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib27","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ejhf.531","article-title":"A\u00a0systems BIOlogy Study to TAilored Treatment in Chronic Heart\u00a0Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF","volume":"18","author":"Voors","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.004_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ejhf.1227","article-title":"Heart failure with preserved ejection fraction in Asia","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.004_bib29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/eurjhf\/hft045","article-title":"Asian Sudden Cardiac Death in Heart\u00a0Failure (ASIAN-HF) registry","volume":"15","author":"Lam","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.004_bib30","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan","volume":"373","author":"Claggett","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2017.11.025","volume":"71","author":"Yancy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.09.004_bib33","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2021.09.004_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2021.09.004_bib35","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","article-title":"Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure","volume":"5","author":"Bassi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2021.09.004_bib36","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.004_bib37","doi-asserted-by":"crossref","first-page":"e003529","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.004_bib38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10557-020-07099-2","article-title":"Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis","volume":"35","author":"Aimo","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jchf.2021.09.004_bib39","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamacardio.2019.1647","article-title":"Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease","volume":"4","author":"Fonarow","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2021.09.004_bib40","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"}],"updated-by":[{"DOI":"10.1016\/j.jchf.2022.02.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000}}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317792100442X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317792100442X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T12:41:54Z","timestamp":1675687314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221317792100442X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S221317792100442X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2021.09.004","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced\u00a0Ejection\u00a0Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}